Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 13/20 | 1.00 |
| ▸ | PLK1 | P53350 | 2/20 | 0.64 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.64 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27939724 | 0.91 | DYRK1A (0.83) | DYRK1APLK1PLK3PLK2MAOA | |
| SCHEMBL2215202 | 0.89 | DYRK1A (0.81) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL12071332 | 0.89 | DYRK1A (0.80) | DYRK1APLK1PLK3PLK2MAOA | |
| SCHEMBL12070347 | 0.89 | DYRK1A (0.80) | DYRK1APLK1PLK3PLK2MAOA | |
| SCHEMBL27921188 | 0.88 | DYRK1A (0.78) | DYRK1APLK1PLK3PLK2MAOA | |
| SCHEMBL27939758 | 0.87 | DYRK1A (0.77) | DYRK1APLK1PLK3PLK2MAOA | |
| SCHEMBL12070348 | 0.86 | DYRK1A (0.75) | DYRK1APLK1PLK3PLK2MAOA | |
| SCHEMBL12070353 | 0.84 | DYRK1A (0.73) | DYRK1APLK1PLK3PLK2MAOA | |
| SCHEMBL27908712 | 0.81 | DYRK1A (0.67) | DYRK1A | |
| SCHEMBL13875091 | 0.79 | DYRK1A (0.65) | DYRK1AMAOAACHEHASPINHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9168247-B2 | Beta carboline derivatives useful in the treatment of proliferative disorders | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2015-10-27 | — | — | US | disclosed |
| US-9168247-B2 | Beta carboline derivatives useful in the treatment of proliferative disorders | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2015-10-27 | — | — | US | disclosed |
| US-9168247-B2 | Beta carboline derivatives useful in the treatment of proliferative disorders | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2015-10-27 | — | — | US | disclosed |
| US-20140005220-A9 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2014-01-02 | — | — | US | disclosed |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-05-09 | — | — | US | disclosed |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-05-09 | — | — | US | disclosed |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-05-09 | — | — | US | disclosed |
| CN-103070862-A | Application of harmine derivative in preparation of antibacterial drugs | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD | 2013-05-01 | — | — | CN | disclosed |
| WO-2011161256-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005220-A9 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CCNI, CCNA1, BRCA1 | DYRK1A 2151/4885PLK1 661/4885PLK3 888/4885 |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CCNI, CCNA1, BRCA1 | DYRK1A 2151/4885PLK1 661/4885PLK3 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.